Notably, FAK activation follows the inhibition of the RAS/RAF/MEK pathway in several preclinical tumor models [50,51,52], a phenomenon also observed in the analysis of patient tumors [53,54]. This evidence concerns the gene MAP2K7 and neoplasm.